摘要
目的观察华蟾素对肺癌患者Th1、Th2及Th17相关血清指标的影响。方法选取2015年6月~2016年6月期间本院收治的68例肺癌患者为观察对象,将其随机分为对照组(常规化疗)34例和观察组(常规化疗加华蟾素)34例,检测两组患者治疗前后的血清Th1、Th2及Th17相关细胞因子水平并进行比较。结果治疗前两组患者的Th1、Th2及Th17相关血清指标均无显著差异,而治疗后观察组的IL-2水平显著高于对照组,INF-γ、TNF-α、IL-4、IL-10、IL-13、IL-17、IL-23、TGF-β水平显著低于同时期对照组(P<0.05)。结论华蟾素可显著地改善肺癌患者的Th1、Th2及Th17相关细胞因子的表达,具有明显的免疫调节作用。
Objective To study and observe the influence of cinobufotalin on the Th1, Th2 and Th17 related serum indexes of patients with lung cancer. Methods A total of 68 patients with lung cancer in our hospital from June 2015 to June 2016 were selected as the observa- tion objects. They were randomly divided into control group （34 cases） and observation group （34 cases）. The control group got conventional lung cancer chemotherapy, while the observation group got conventional chemotherapy plus cinobufotalin. Detected and compared the serum levels of the Th1, Th2 and Th17 related factors of the two groups before and after the treatment. Results Before treatment, there was no sig- nificant difference in serum levels of Th1, Th2 and Th17. After treatment, the level of IL-2 in the observation group was significantly higher than in the control group, while the levels of INF-γ, TNF-α, IL--4, IL-10, IL-13, IL-17, IL-23 and TGF-β were significantly lower in the observation group than in the control group at the same time （P 〈 0.05）. Conclusion The cinobufotalin could significantly improve the serum expression of Th1, Th2 and Th 17 related factors of patients with lung cancer. It played a distinct role of immuneregulation to the patients.
出处
《肿瘤药学》
CAS
2017年第2期235-239,共5页
Anti-Tumor Pharmacy
基金
宜宾市科技局项目资助(2013SF003)
四川省科技厅项目资助(2013JY0171)
湖南省中医药科研计划项目立项项目(201768)
